Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | USP2 | O75604 | 3/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | RECQL | P46063 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | BLM | P54132 | 3/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | THRB | P10828 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | RGS12 | O14924 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5324040 | 1.00 | KDM4E (0.54) | KDM4EMAPTUSP2HIF1AALOX15 | |
| SCHEMBL7277608 | 0.90 | THRB (0.45) | KDM4EMAPTUSP2HIF1AALOX15 | |
| SCHEMBL3467175 | 0.88 | SLC7A5 (0.54) | KDM4EMAPTUSP2HIF1AALOX15 | |
| SCHEMBL3467173 | 0.88 | SLC7A5 (0.54) | KDM4EMAPTUSP2HIF1AALOX15 | |
| SCHEMBL9838984 | 0.87 | KDM4E (0.51) | KDM4EMAPTUSP2HIF1AALOX15 | |
| SCHEMBL20299961 | 0.85 | THRB (0.50) | KDM4EMAPTUSP2HIF1AALOX15 | |
| SCHEMBL6339538 | 0.85 | KDM4E (0.50) | KDM4EMAPTUSP2HIF1AALOX15 | |
| SCHEMBL18035896 | 0.84 | USP2 (0.47) | KDM4EMAPTUSP2HIF1AALOX15 | |
| SCHEMBL29216329 | 0.79 | KDM4E (0.58) | KDM4EMAPTUSP2HIF1AALOX15 | |
| SCHEMBL454801 | 0.79 | KDM4E (0.58) | KDM4EMAPTUSP2HIF1AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421276-B2 | Methods of treating neurodegenerative disease with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues | ATHIRA PHARMA, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2023182469-A1 | METHOD FOR PRODUCING METHYL PHENOL | 三菱ケミカル株式会社 | 2023-09-28 | — | — | WO | disclosed |
| CN-116731101-A | Derivatives of N-caproic acid-L-tyrosine-L-isoleucine- (6) -aminocaproamide for the treatment of various diseases | 雅斯娜 | 2023-09-12 | — | — | CN | disclosed |
| CN-116655730-A | Derivatives of N-caproic acid-L-tyrosine-L-isoleucine- (6) -aminocaproamide for the treatment of various diseases | 雅斯娜 | 2023-08-29 | — | — | CN | disclosed |
| CN-109563144-B | Compound (I) | 雅斯娜 | 2023-03-28 | — | — | CN | disclosed |
| EP-4067368-A1 | COMPOUNDS | Athira Pharma, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-3464336-B1 | COMPOUNDS | ATHIRA PHARMA INC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20210340176-A1 | Compounds | ATHIRA PHARMA, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| US-11021514-B2 | Compounds | ATHIRA PHARMA, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3464336-A1 | COMPOUNDS | M3 Biotechnology, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| CN-109563144-A | Compound (I) | M3生物技术公司 | 2019-04-02 | — | — | CN | disclosed |
| WO-2017210489-A1 | COMPOUNDS | M3 BIOTECHNOLOGY, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021514-B2 | Compounds | BACE1, BDNF, CLN6 | KDM4E 4184/4885MAPT 42/4885USP2 4109/4885 |
| US-20210340176-A1 | Compounds | BACE1, BDNF, CLN6 | KDM4E 4184/4885MAPT 42/4885USP2 4109/4885 |
| US-12421276-B2 | Methods of treating neurodegenerative disease with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues | AADAT, ABAT, IAPP | KDM4E 3296/4885MAPT 48/4885USP2 2764/4885 |
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | KDM4E 2053/4885MAPT 3794/4885USP2 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.